Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/16416
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDavis, Joshua S-
dc.contributor.authorSud, Archana-
dc.contributor.authorO'Sullivan, Matthew VN-
dc.contributor.authorRobinson, James O-
dc.contributor.authorFerguson, Patricia E-
dc.contributor.authorFoo, Hong-
dc.contributor.authorvan Hal, Sebastiaan J-
dc.contributor.authorRalph, Anna P-
dc.contributor.authorHowden, Benjamin P-
dc.contributor.authorBinks, Paula M-
dc.contributor.authorKirby, Adrienne-
dc.contributor.authorTong, Steven YC-
dc.contributor.authorCombination Antibiotics for MEthicillin Resistant Staphylococcus aureus (CAMERA) study group-
dc.contributor.authorAustralasian Society for Infectious Diseases Clinical Research Network-
dc.date2015-09-08-
dc.date.accessioned2016-11-16T05:07:31Z-
dc.date.available2016-11-16T05:07:31Z-
dc.date.issued2016-01-15-
dc.identifier.citationClinical Infectious Diseases 2016; 62(2): 173-180en_US
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/16416-
dc.description.abstractBACKGROUND: In vitro laboratory and animal studies demonstrate a synergistic role for the combination of vancomycin and antistaphylococcal β-lactams for methicillin-resistant Staphylococcus aureus (MRSA) bacteremia. Prospective clinical data are lacking. METHODS: In this open-label, multicenter, clinical trial, adults with MRSA bacteremia received vancomycin 1.5 g intravenously twice daily and were randomly assigned (1:1) to receive intravenous flucloxacillin 2 g every 6 hours for 7 days (combination group) or no additional therapy (standard therapy group). Participants were stratified by hospital and randomized in permuted blocks of variable size. Randomization codes were kept in sealed, sequentially numbered, opaque envelopes. The primary outcome was the duration of MRSA bacteremia in days. RESULTS: We randomly assigned 60 patients to receive vancomycin (n = 29), or vancomycin plus flucloxacillin (n = 31). The mean duration of bacteremia was 3.00 days in the standard therapy group and 1.94 days in the combination group. According to a negative binomial model, the mean time to resolution of bacteremia in the combination group was 65% (95% confidence interval, 41%-102%; P = .06) that in the standard therapy group. There was no difference in the secondary end points of 28- and 90-day mortality, metastatic infection, nephrotoxicity, or hepatotoxicity. CONCLUSIONS: Combining an antistaphylococcal β-lactam with vancomycin may shorten the duration of MRSA bacteremia. Further trials with a larger sample size and objective clinically relevant end points are warranted. Australian New Zealand Clinical Trials Registry: ACTRN12610000940077 (www.anzctr.org.au)en_US
dc.subjectAnti-bacterial agentsen_US
dc.subjectBacteremiaen_US
dc.subjectFloxacillin - pharmacologyen_US
dc.subjectStaphylococcal infections - drug therapyen_US
dc.subjectVancomycin - pharmacologyen_US
dc.subjectMethicillin-resistant staphylococcus aureus - isolation & purificationen_US
dc.titleCombination of vancomycin and β-lactam therapy for methicillin-resistant staphylococcus aureus bacteremia: a pilot multicenter randomized controlled trialen_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleClinical Infectious Diseasesen_US
dc.identifier.affiliationGlobal and Tropical Health Division, Menzies School of Health Research, Casuarina, Northern Territory, Australiaen_US
dc.identifier.affiliationDepartment of Infectious Diseases, Royal Darwin Hospital, Darwin, Northern Territory, Australiaen_US
dc.identifier.affiliationDepartment of Infectious Diseases, John Hunter Hospital, Newcastle, NSW, Australiaen_US
dc.identifier.affiliationDepartment of Infectious Diseases, Nepean Hospital and University of Sydney, Kingswood, NSW, Australiaen_US
dc.identifier.affiliationMarie Bashir Institute for Infectious Diseases and Biosecurity, University of Sydney, Sydney, NSW, Australiaen_US
dc.identifier.affiliationNational Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, NSW, Australiaen_US
dc.identifier.affiliationCentre for Infectious Diseases and Microbiology, Westmead Hospital, Westmead, NSW, Australiaen_US
dc.identifier.affiliationDepartment of Infectious Diseases, Blacktown Hospital, Blacktown, NSW, Australiaen_US
dc.identifier.affiliationDepartment of Microbiology and Infectious Diseases, Liverpool Hospital, Liverpool, NSW, Australiaen_US
dc.identifier.affiliationDepartment Microbiology and Infectious Diseases, Royal Prince Alfred Hospital, Sydney, NSW, Australiaen_US
dc.identifier.affiliationDepartment of Microbiology and Infectious Diseases, PathWest Laboratory Medicine WA, Royal Perth Hospital and Fiona Stanley Hospital, Perth, Western Australia, Australiaen_US
dc.identifier.affiliationAustralian Collaborating Centre for Enterococcus and Staphylococcus Species (ACCESS) Typing and Research, School of Veterinary and Life Sciences, Murdoch University, Perth, Western Australia, Australiaen_US
dc.identifier.affiliationSchool of Biomedical Sciences, Curtin University, Perth, Western Australia, Australiaen_US
dc.identifier.affiliationDepartment of Microbiology and Immunology, Microbiological Diagnostic Unit, The University of Melbourne at the Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australiaen_US
dc.identifier.affiliationMicrobiologyen_US
dc.identifier.affiliationDepartment of Microbiology, Monash University, Melbourne, Victoria, Australiaen_US
dc.identifier.affiliationInfectious Diseasesen_US
dc.type.studyortrialMulticentre Studiesen_US
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/26349552en_US
dc.identifier.doi10.1093/cid/civ808en_US
dc.type.contentTexten_US
dc.type.austinJournal Articleen_US
local.name.researcherHowden, Benjamin P
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.openairetypeJournal Article-
crisitem.author.deptInfectious Diseases-
crisitem.author.deptMicrobiology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

94
checked on Dec 25, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.